THORNTON JOSEPH CLAY sold $21K of CLOV

THORNTON JOSEPH CLAY (Interim CFO) sold 4,591 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.68 on 2026-10-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · THORNTON JOSEPH CLAY
Published Oct 19, 2026, 8:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Bearish
medium confidence
Mentioned
$CLOV
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVBearishLow
01

Why it matters

The filing provides the first public notice of the CFO's share sale, a primary source event.

02

Market read

A modest insider sale by a senior officer may cause slight short‑term pressure but is unlikely to move the stock materially.

03

What to watch

Potential upcoming earnings or strategic announcements could amplify the effect of the insider sale.

Relevance 2/10Novelty 2/10Timing: after-hours filing on 2026-10-19

Background

Clover Health Investments filed a Form 4 disclosure of an insider transaction by its interim CFO.

Company-level read

Ticker impact

$CLOVBearishMedium confidence
Context

Form 4 shows CFO Thornton Joseph Clay sold 4,591 shares for $21,485, reducing his stake to 1,244,935 shares.

Expected impact

likely modest downward pressure as investors digest the CFO's sale

Evidence & confidence

The sale is modest in dollar terms but involves a senior officer, which can influence short‑term sentiment.

Market effects

Minimal impact on health‑tech sector; similar insider sales have not moved the broader index.

U.S. market only; no regional ripple.

Low; isolated company event.

Counterpoint

The sale may be routine portfolio rebalancing; price impact could be negligible.

Key entities

  • Clover Health Investments, Corp.

    US‑listed health‑tech firm (ticker CLOV).

  • Thornton Joseph Clay

    Interim CFO of Clover Health.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$CLOVHighAI 8/10

Clover Health (CLOV) Q3 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.